Literature DB >> 12772286

Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation.

Georgette Thumshirn1, Ulrich Hersel, Simon L Goodman, Horst Kessler.   

Abstract

The alpha v beta 3 integrin receptor plays an important role in human metastasis and tumor-induced angiogenesis. Targeting this receptor may provide information about the receptor status of the tumor and enable specific therapeutic planning. Solid-phase peptide synthesis of multimeric cyclo(-RGDfE-)-peptides is described, which offer the possibility of enhanced integrin targeting due to polyvalency effects. These peptides contain an aminooxy group for versatile chemoselective oxime ligation. Conjugation with para-trimethylstannylbenzaldehyde results in a precursor for radioiododestannylation, which would allow them to be used as potential tools for targeting and imaging alpha v beta 3-expressing tumor cells. The conjugates were obtained in good yield without the need of a protection strategy and under mild conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12772286     DOI: 10.1002/chem.200204304

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  65 in total

1.  Advantages of RGD peptides for directing cell association with biomaterials.

Authors:  Susan L Bellis
Journal:  Biomaterials       Date:  2011-06       Impact factor: 12.479

2.  Application of click-click chemistry to the synthesis of new multivalent RGD conjugates.

Authors:  Mathieu Galibert; Lucie Sancey; Olivier Renaudet; Jean-Luc Coll; Pascal Dumy; Didier Boturyn
Journal:  Org Biomol Chem       Date:  2010-09-09       Impact factor: 3.876

3.  Regiospecific syntheses of functionalized diaryliodonium tosylates via [hydroxy(tosyloxy)iodo]arenes generated in situ from (diacetoxyiodo)arenes.

Authors:  Joong-Hyun Chun; Victor W Pike
Journal:  J Org Chem       Date:  2012-02-09       Impact factor: 4.354

4.  In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.

Authors:  Lucie Sancey; Valérie Ardisson; Laurent M Riou; Mitra Ahmadi; Danièle Marti-Batlle; Didier Boturyn; Pascal Dumy; Daniel Fagret; Catherine Ghezzi; Jean-Philippe Vuillez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-04       Impact factor: 9.236

Review 5.  Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?

Authors:  Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

6.  Design, synthesis, and validation of a branched flexible linker for bioactive peptides.

Authors:  Martina E Bowen; Yasunari Monguchi; Rajesh Sankaranarayanan; Josef Vagner; Lucinda J Begay; Liping Xu; Bhumasamudram Jagadish; Victor J Hruby; Robert J Gillies; Eugene A Mash
Journal:  J Org Chem       Date:  2007-02-06       Impact factor: 4.354

7.  Rigid multivalent scaffolds based on adamantane.

Authors:  Khaled Nasr; Nadine Pannier; John V Frangioni; Wolfgang Maison
Journal:  J Org Chem       Date:  2008-01-08       Impact factor: 4.354

8.  2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics.

Authors:  Jiyun Shi; Young-Seung Kim; Sudipta Chakraborty; Bing Jia; Fan Wang; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-07-15       Impact factor: 4.774

9.  Efficient method for site-specific 18F-labeling of biomolecules using the rapid condensation reaction between 2-cyanobenzothiazole and cysteine.

Authors:  Jongho Jeon; Bin Shen; Liqin Xiong; Zheng Miao; Kyung Hyun Lee; Jianghong Rao; Frederick T Chin
Journal:  Bioconjug Chem       Date:  2012-08-10       Impact factor: 4.774

10.  In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.

Authors:  Calogero D'Alessandria; Karolin Pohle; Florian Rechenmacher; Stefanie Neubauer; Johannes Notni; Hans-Jürgen Wester; Markus Schwaiger; Horst Kessler; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.